Literature DB >> 35819498

Assessing dynamic metabolic heterogeneity in non-small cell lung cancer patients via ultra-high sensitivity total-body [18F]FDG PET/CT imaging: quantitative analysis of [18F]FDG uptake in primary tumors and metastatic lymph nodes.

DaQuan Wang1, Xu Zhang2, Bo Qiu1, SongRan Liu3, Hui Liu7, ChaoJie Zheng4, Jia Fu3, YiWen Mo2, NaiBin Chen1, Rui Zhou1, Chu Chu1, FangJie Liu1, JinYu Guo1, Yin Zhou5, Yun Zhou4, Wei Fan6, Hui Liu7.   

Abstract

PURPOSE: This study aimed to quantitatively assess [18F]FDG uptake in primary tumor (PT) and metastatic lymph node (mLN) in newly diagnosed non-small cell lung cancer (NSCLC) using the total-body [18F]FDG PET/CT and to characterize the dynamic metabolic heterogeneity of NSCLC.
METHODS: The 60-min dynamic total-body [18F]FDG PET/CT was performed before treatment. The PTs and mLNs were manually delineated. An unsupervised K-means classification method was used to cluster patients based on the imaging features of PTs. The metabolic features, including Patlak-Ki, Patlak-Intercept, SUVmean, metabolic tumor volume (MTV), total lesion glycolysis (TLG), and textural features, were extracted from PTs and mLNs. The targeted next-generation sequencing of tumor-associated genes was performed. The expression of Ki67, CD3, CD8, CD34, CD68, and CD163 in PTs was determined by immunohistochemistry.
RESULTS: A total of 30 patients with stage IIIA-IV NSCLC were enrolled. Patients were divided into fast dynamic FDG metabolic group (F-DFM) and slow dynamic FDG metabolic group (S-DFM) by the unsupervised K-means classification of PTs. The F-DFM group showed significantly higher Patlak-Ki (P < 0.001) and SUVmean (P < 0.001) of PTs compared with the S-DFM group, while no significant difference was observed in Patlak-Ki and SUVmean of mLNs between the two groups. The texture analysis indicated that PTs in the S-DFM group were more heterogeneous in FDG uptake than those in the F-DFM group. Higher T cells (CD3+/CD8+) and macrophages (CD68+/CD163+) infiltration in the PTs were observed in the F-DFM group. No significant difference was observed in tumor mutational burden between the two groups.
CONCLUSION: The dynamic total-body [18F]FDG PET/CT stratified NSCLC patients into the F-DFM and S-DFM groups, based on Patlak-Ki and SUVmean of PTs. PTs in the F-DFM group seemed to be more homogenous in terms of [18F]FDG uptake than those in the S-DFM group. The higher infiltrations of T cells and macrophages were observed in the F-DFM group, which suggested a potential benefit from immunotherapy.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Dynamic total-body PET; Lung cancer; Metabolic heterogeneity; [18F]FDG

Year:  2022        PMID: 35819498     DOI: 10.1007/s00259-022-05904-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   10.057


  40 in total

1.  Regional Lymph Node Uptake of [(18)F]Fluorodeoxyglucose After Definitive Chemoradiation Therapy Predicts Local-Regional Failure of Locally Advanced Non-Small Cell Lung Cancer: Results of ACRIN 6668/RTOG 0235.

Authors:  Stephanie Markovina; Fenghai Duan; Bradley S Snyder; Barry A Siegel; Mitchell Machtay; Jeffrey D Bradley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-11-01       Impact factor: 7.038

2.  Metabolic activity by 18F-FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC.

Authors:  Kyoichi Kaira; Tetsuya Higuchi; Ichiro Naruse; Yukiko Arisaka; Azusa Tokue; Bolag Altan; Satoshi Suda; Akira Mogi; Kimihiro Shimizu; Noriaki Sunaga; Takeshi Hisada; Shigehisa Kitano; Hideru Obinata; Takehiko Yokobori; Keita Mori; Masahiko Nishiyama; Yoshihito Tsushima; Takayuki Asao
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-21       Impact factor: 9.236

3.  Intratumoral heterogeneity of (18)F-FDG uptake predicts survival in patients with pancreatic ductal adenocarcinoma.

Authors:  Seung Hyup Hyun; Ho Seong Kim; Seong Ho Choi; Dong Wook Choi; Jong Kyun Lee; Kwang Hyuck Lee; Joon Oh Park; Kyung-Han Lee; Byung-Tae Kim; Joon Young Choi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-02-12       Impact factor: 9.236

4.  Spectral Clustering Predicts Tumor Tissue Heterogeneity Using Dynamic 18F-FDG PET: A Complement to the Standard Compartmental Modeling Approach.

Authors:  Prateek Katiyar; Mathew R Divine; Ursula Kohlhofer; Leticia Quintanilla-Martinez; Bernhard Schölkopf; Bernd J Pichler; Jonathan A Disselhorst
Journal:  J Nucl Med       Date:  2016-11-03       Impact factor: 10.057

5.  Visual versus quantitative assessment of intratumor 18F-FDG PET uptake heterogeneity: prognostic value in non-small cell lung cancer.

Authors:  Florent Tixier; Mathieu Hatt; Clemence Valla; Vincent Fleury; Corinne Lamour; Safaa Ezzouhri; Pierre Ingrand; Remy Perdrisot; Dimitris Visvikis; Catherine Cheze Le Rest
Journal:  J Nucl Med       Date:  2014-06-05       Impact factor: 10.057

6.  Heterogeneity in tumours: Validating the use of radiomic features on 18F-FDG PET/CT scans of lung cancer patients as a prognostic tool.

Authors:  Marie Manon Krebs Krarup; Lotte Nygård; Ivan Richter Vogelius; Flemming Littrup Andersen; Gary Cook; Vicky Goh; Barbara Malene Fischer
Journal:  Radiother Oncol       Date:  2019-11-14       Impact factor: 6.280

7.  Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?

Authors:  Gary J R Cook; Connie Yip; Muhammad Siddique; Vicky Goh; Sugama Chicklore; Arunabha Roy; Paul Marsden; Shahreen Ahmad; David Landau
Journal:  J Nucl Med       Date:  2012-11-30       Impact factor: 10.057

8.  Tumor Heterogeneity in Lung Cancer: Assessment with Dynamic Contrast-enhanced MR Imaging.

Authors:  Soon Ho Yoon; Chang Min Park; Sang Joon Park; Jeong-Hwa Yoon; Seokyung Hahn; Jin Mo Goo
Journal:  Radiology       Date:  2016-03-31       Impact factor: 11.105

Review 9.  Beyond tissue biopsy: a diagnostic framework to address tumor heterogeneity in lung cancer.

Authors:  Wieland Voigt; Christian Manegold; Lothar Pilz; Yi-Long Wu; Leonard Müllauer; Robert Pirker; Martin Filipits; Jacek Niklinski; Lubos Petruzelka; Helmut Prosch
Journal:  Curr Opin Oncol       Date:  2020-01       Impact factor: 3.645

10.  Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer.

Authors:  Won-Chul Lee; Lixia Diao; Jing Wang; Jianhua Zhang; Emily B Roarty; Susan Varghese; Chi-Wan Chow; Junya Fujimoto; Carmen Behrens; Tina Cascone; Weiyi Peng; Neda Kalhor; Cesar A Moran; Annikka Weissferdt; Faye M Johnson; William N William; Stephen G Swisher; J Jack Lee; Waun Ki Hong; John V Heymach; Ignacio I Wistuba; P Andrew Futreal; Jianjun Zhang
Journal:  Mod Pathol       Date:  2018-02-06       Impact factor: 7.842

View more
  1 in total

Review 1.  Glycolysis in tumor microenvironment as a target to improve cancer immunotherapy.

Authors:  Chu Xiao; He Tian; Yujia Zheng; Zhenlin Yang; Shuofeng Li; Tao Fan; Jiachen Xu; Guangyu Bai; Jingjing Liu; Ziqin Deng; Chunxiang Li; Jie He
Journal:  Front Cell Dev Biol       Date:  2022-09-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.